Mytos
Generated by Meeveem AI
"Mytos automates stem cell therapy production for regenerative medicine at scale"
About Mytos
Mytos builds automation technology for stem cell manufacturing and operates an automated contract development and manufacturing service for regenerative medicines. Its iDEM system automates coating, seeding, feeding, imaging, passaging and harvesting, helping developers scale production consistently and reduce manufacturing costs. The company was founded in London in 2016.
Its first manufacturing facility is housed within Cell and Gene Therapy Catapult’s Stevenage Manufacturing Innovation Centre. Partners include Aspen Neuroscience on Parkinson's disease, StemSight on vision loss, Rinri Therapeutics on hearing loss and Novadip on bone repair. Mytos combines cell culture automation with process development and manufacturing support, working with developers from preclinical programmes towards clinical and commercial supply.
Scientists and engineers together
Mytos brings together scientists, engineers and clinical manufacturing specialists. Its teams span biology, hardware, software, product, quality and operations, combining laboratory process knowledge with the design and manufacture of automation systems.
From a process to manufacturing
The company’s service starts with a pilot to establish technical fit, followed by translating the customer’s process onto iDEM. Process and analytical development, regulatory documentation and clinical manufacturing support connect the automation platform with the requirements of therapy developers.
42
Team Members
2016
Founded
Biotechnology
Sector
On-Site
Work Environment